Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and ...

Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk ...

Medicare cover GLP-1s under a Trump-negotiated pricing plan starting in 2026, lowering costs for key obesity and diabetes drugs.

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

Novo Nordisk offers Ozempic Wegovy sold 199 per month for new self-paying patients from Nov. 17 to March 31 with discounted initial doses.

The drugs have become popular for their significant weight-loss effects, but their high cost has made them inaccessible for ...